Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023

10/19/23 6:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KRTX alert in real time by email

Karuna Therapeutics, Inc. (NASDAQ:KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, November 2, 2023 at 8:00 a.m. ET to review third quarter 2023 financial results and provide a general business update.

A live webcast of the presentation will be available on the Investor Relations page of Karuna's website at investors.karunatx.com. A replay of the webcast will also be archived for up to 30 days on Karuna's website following the completion of the event.

About Karuna Therapeutics

Karuna Therapeutics is a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by serious mental illness. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives. For more information, please visit www.karunatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231019342719/en/

Get the next $KRTX alert in real time by email

Recent Analyst Ratings for

$KRTX

Date	Price Target	Rating	Analyst
12/12/2023	$291.00	Buy	Citigroup
12/12/2023	$227.00	Buy	Deutsche Bank
8/22/2023	$225.00	Overweight	Wells Fargo
7/20/2023	$280.00	Overweight	Morgan Stanley
3/8/2023	$214.00	Neutral	Cantor Fitzgerald
1/27/2023	$209.00	Neutral	UBS
1/5/2023	$285.00	Overweight	Piper Sandler
11/1/2022	$288.00	Buy	Loop Capital

More analyst ratings

Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023

Chat with this insight

Recent Analyst Ratings for
$KRTX

$KRTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Healy James returned $466,830,870 worth of shares to the company (1,414,639 units at $330.00), closing all direct ownership in the company (SEC Form 4)

Pande Atul returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)

Brown Jason Parker returned $6,985,110 worth of shares to the company (21,167 units at $330.00), closing all direct ownership in the company (SEC Form 4)

$KRTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Karuna Therapeutics with a new price target

Deutsche Bank initiated coverage on Karuna Therapeutics with a new price target

Wells Fargo initiated coverage on Karuna Therapeutics with a new price target

$KRTX
SEC Filings

SEC Form 15-12G filed by Karuna Therapeutics Inc.

SEC Form S-8 POS filed by Karuna Therapeutics Inc.

SEC Form S-8 POS filed by Karuna Therapeutics Inc.

$KRTX
Financials

Live finance-specific insights

PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion

Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics